Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications

Fig. 5

Tegaserod (TM) decreases tumor infiltration of CD25+CD4+ T cells and synergizes with Vemurafenib and Cobimetinib. a-c C57BL/6 J mice were subcutaneously injected with 5 × 105 B16F10 cells. Seven days post-tumor injection, mice were randomized and into two groups and treated daily with 5 mg/kg of Tegaserod or vehicle for five consecutive days. Mice were sacrificed on Day 13 post tumor-inoculation and tumor infiltrating lymphocytes using were assessed using FACS analysis (n = 3–6). d Melanoma cell lines harboring the BRAFV600E mutation, A375, RPMI-7951 (RPMI) and SK-MEL-24 were exposed to a dose range of TM and Vemurafenib in a fixed 1:1 ratio. BRAFV600E and BRAF WT melanoma cell lines were exposed to a dose range of TM and Cobimetinib in a fixed ratio (RPMI, 1:2, A375 64:1, MeWo 4:1, MEL-JUSO 4:1, B16F10 1:1). Synergy was evaluated using the combination index (CI) from the dose-response curves. CI < 1 indicates synergy, CI = 1 indicates additivity, and CI > 1 indicates antagonism. The EC50 (50% effective concentration) and EC75 (75% effective concentration) or EC90 (90% effective concentration) are shown (n = 3–6). *P < 0.05 as determined by a one-sample Student’s t-test

Back to article page